Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
152.80    -0.20 (-0.13%)
Bid:
153.20
Ask:
153.60
Spread: 0.40 (0.261%)
Market Cap: £874.50m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Q3 Trading Update

26 Oct 2022 07:00

RNS Number : 0982E
Elementis PLC
26 October 2022
 

26 October 2022.

Elementis plc

Q3 Trading Update

Trading in line with expectations - outlook unchanged

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues a trading update for the three months ended 30 September 2022.

Third quarter business performance

 

The Group delivered a good performance in the third quarter, with double-digit revenue growth on an underlying basis, driven by further strong performances in Personal Care and Coatings, where the focus on innovation, new product development and new business opportunities, underpinned by strong key account relationships and supply resiliency, continued to deliver sales growth. The Chromium business also performed well in the quarter whilst the Talc business continued to be impacted by weakness in European markets.

 

Overall the Group saw strong performances in the Americas, with lower demand in Europe and continuing market weakness in China. The full year outlook for the Group remains unchanged.

 

· Coatings delivered a solid third quarter performance. Pricing actions continued to offset raw material and energy cost increases and protect margins. Sales growth was driven by new business wins at key accounts and market share gains, with new products gaining further traction The business remains on track to deliver full year performance significantly ahead of last year.

 

· Personal Care continued to perform strongly in the third quarter, with market demand and pricing actions in both Cosmetics and AP Actives driving strong sales growth and margin expansion versus the prior year period. Whilst normal seasonality and some moderation of demand is expected in the fourth quarter, the business is expected to deliver full year performance substantially ahead of last year.

 

· Talc performance in the third quarter was impacted by continuing weaker demand in European end markets, in particular automotive, reduced ceramics demand in China, and the loss of sales into Russia and neighbouring countries. Higher energy and logistics costs, as well as adverse currency movements, were offset by new business wins and price increases which will continue to be implemented through the rest of the year.

· Chromium sales in the third quarter were ahead of the prior year period, reflecting solid demand and price increases. Global industry utilization remains high, with improved pricing and lower chrome ore prices offsetting higher energy and logistics costs. An update on the strategic review of the Chromium business is expected around the calendar year end, as previously indicated.

 

Outlook

 

The full year outlook for the Group remains unchanged, with Group leverage lower.

 

Despite weakening underlying macro-economic conditions creating further headwinds, particularly in Europe, the Group's continued focus on innovation and new business opportunities, along with further pricing actions and operating efficiencies, is expected to deliver full year financial performance in line with our expectations.

 

 

 

Commenting on the third quarter performance, CEO, Paul Waterman said,

"We delivered a good third quarter performance, with our focus on product innovation, customer relationships, value pricing and operating efficiency continuing to create real momentum in our business. This is enabling us to weather the macroeconomic headwinds affecting a number of our markets, and deliver sales growth and margin expansion in line with our expectations.

We expect the market environment to remain challenging, but are confident that by continuing to execute effectively on our strategy we will make further progress towards achieving our medium-term goals."

 

Enquiries

Elementis plc

David Boyd, Investor Relations Tel: 0207 067 2994

David.boyd.ext@elementis.com Mob:+44 7764 905135

 

Tulchan

Martin Robinson Tel: 020 7353 4200

Olivia Peters

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTMABLTMTATBBT
Date   Source Headline
8th Jun 20265:14 pmRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSCommencement of share buyback programme
2nd Jun 20267:00 amRNSSale of Pharma business & intended buyback launch
1st Jun 20269:58 amRNSTotal Voting Rights
5th May 20265:26 pmRNSHolding(s) in Company
1st May 20269:59 amRNSTotal Voting Rights
29th Apr 20263:47 pmRNSResult of AGM
29th Apr 20267:00 amRNSFirst quarter trading update
8th Apr 20264:14 pmRNSDirector/PDMR Shareholding
7th Apr 20263:06 pmRNSDirector/PDMR Shareholding
1st Apr 202610:18 amRNSTotal Voting Rights
30th Mar 20265:06 pmRNSCorrection - Admission to Trading
30th Mar 20261:58 pmRNSAdmission to Trading
26th Mar 202612:09 pmRNSNotice of AGM and Annual Report & Accounts
19th Mar 20267:00 amRNSDirectorate change
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:39 pmRNSDirector/PDMR Shareholding
9th Mar 20265:14 pmRNSHolding(s) in Company
5th Mar 20265:11 pmRNSBlocklisting Interim Review
5th Mar 20264:57 pmRNSPreliminary Results - Correction
5th Mar 20267:00 amRNSPreliminary Results
2nd Mar 202610:00 amRNSTotal Voting Rights
25th Feb 20264:22 pmRNSDirectorate change
2nd Feb 202610:05 amRNSTotal Voting Rights
21st Jan 20267:00 amRNSTrading Update
2nd Jan 202611:10 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSConfirmation of Board changes
2nd Jan 20267:00 amRNSConfirmation of Board changes
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSCompletion of Buyback programme
15th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:35 pmRNSTransaction in Own Shares
10th Dec 20256:12 pmRNSTransaction in Own Shares
9th Dec 20255:55 pmRNSTransaction in Own Shares
8th Dec 20255:52 pmRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20256:06 pmRNSTransaction in Own Shares
3rd Dec 20255:28 pmRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20255:49 pmRNSTransaction in Own Shares
28th Nov 20255:49 pmRNSTransaction in Own Shares
27th Nov 20255:40 pmRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSElementis acquires personal care specialist
25th Nov 20255:44 pmRNSTransaction in Own Shares
24th Nov 20256:01 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.